Pidotimod in allergic diseases.
Adaptive Immunity
Adjuvants, Immunologic
/ pharmacology
Adolescent
Asthma
/ drug therapy
Child
Child, Preschool
Chronic Urticaria
/ drug therapy
Dermatitis, Atopic
/ drug therapy
Desensitization, Immunologic
Food Hypersensitivity
/ drug therapy
Humans
Hypersensitivity
/ drug therapy
Immunity, Innate
/ drug effects
Immunologic Factors
/ pharmacology
Pyrrolidonecarboxylic Acid
/ analogs & derivatives
Rhinitis, Allergic
/ drug therapy
Thiazolidines
/ pharmacology
Journal
Minerva pediatrica
ISSN: 1827-1715
Titre abrégé: Minerva Pediatr
Pays: Italy
ID NLM: 0400740
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
pubmed:
1
8
2020
medline:
6
10
2021
entrez:
1
8
2020
Statut:
ppublish
Résumé
The rising incidence of allergic disease requires more specific, effective and safe therapeutic strategies. In this regard, several kinds of biologically active substances, commonly known as immunostimulants, have been introduced for the prevention and treatment of allergic diseases in pediatric population. Among the heterogeneous group of biologically active molecules to date available, pidotimod (Axil, Valeas S.p.A, Milan) is proved to be able to ameliorate both innate and adaptive immunity and enhances the immune system properties often impaired in patients with allergic disorders.
Identifiants
pubmed: 32731733
pii: S0026-4946.20.05967-8
doi: 10.23736/S0026-4946.20.05967-8
doi:
Substances chimiques
Adjuvants, Immunologic
0
Immunologic Factors
0
Thiazolidines
0
pidotimod
785363R681
Pyrrolidonecarboxylic Acid
SZB83O1W42
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM